NEKTAR THERAPEUTICS's ticker is NKTR and the CUSIP is 640268108. A total of 184 filers reported holding NEKTAR THERAPEUTICS in Q2 2015. The put-call ratio across all filers is 0.83 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2022 | $21,560,000 | -57.4% | 4,000,000 | +6.7% | 0.78% | -55.2% |
| Q4 2021 | $50,663,000 | -24.8% | 3,750,000 | 0.0% | 1.74% | -16.1% |
| Q3 2021 | $67,350,000 | +12.1% | 3,750,000 | +7.1% | 2.07% | +2.5% |
| Q2 2021 | $60,060,000 | +50.2% | 3,500,000 | +75.0% | 2.02% | +47.4% |
| Q1 2021 | $40,000,000 | -5.9% | 2,000,000 | -20.0% | 1.37% | -8.0% |
| Q4 2020 | $42,500,000 | -48.8% | 2,500,000 | -50.0% | 1.49% | -31.8% |
| Q3 2020 | $82,950,000 | +19.4% | 5,000,000 | +66.7% | 2.19% | -45.0% |
| Q2 2020 | $69,480,000 | +29.7% | 3,000,000 | 0.0% | 3.98% | +24.3% |
| Q1 2020 | $53,550,000 | -33.8% | 3,000,000 | -20.0% | 3.20% | -22.4% |
| Q4 2019 | $80,944,000 | +48.1% | 3,750,000 | +25.0% | 4.12% | +43.3% |
| Q3 2019 | $54,645,000 | -38.6% | 3,000,000 | +20.0% | 2.87% | -30.7% |
| Q2 2019 | $88,950,000 | +32.4% | 2,500,000 | +25.0% | 4.15% | +23.8% |
| Q1 2019 | $67,200,000 | +2.2% | 2,000,000 | 0.0% | 3.35% | +7.3% |
| Q4 2018 | $65,740,000 | -28.1% | 2,000,000 | +33.3% | 3.12% | -20.3% |
| Q3 2018 | $91,440,000 | -6.4% | 1,500,000 | -25.0% | 3.91% | +4.1% |
| Q2 2018 | $97,660,000 | -38.7% | 2,000,000 | +33.3% | 3.76% | -52.0% |
| Q1 2018 | $159,390,000 | -20.3% | 1,500,000 | -55.2% | 7.82% | -20.1% |
| Q4 2017 | $200,062,000 | +60.3% | 3,350,000 | -35.6% | 9.79% | +23.8% |
| Q3 2017 | $124,800,000 | +19.3% | 5,200,000 | -2.8% | 7.91% | +55.3% |
| Q2 2017 | $104,593,000 | -17.5% | 5,350,000 | -0.9% | 5.09% | -0.9% |
| Q1 2017 | $126,738,000 | +72.2% | 5,400,000 | -10.0% | 5.14% | +34.1% |
| Q4 2016 | $73,620,000 | +33.9% | 6,000,000 | +87.5% | 3.83% | +58.6% |
| Q3 2016 | $54,976,000 | -9.1% | 3,200,000 | -24.7% | 2.42% | -17.3% |
| Q2 2016 | $60,478,000 | -2.3% | 4,250,000 | -5.6% | 2.92% | -19.3% |
| Q1 2016 | $61,875,000 | +4.9% | 4,500,000 | +28.6% | 3.62% | -4.9% |
| Q4 2015 | $58,975,000 | +139.2% | 3,500,000 | +55.6% | 3.81% | +80.4% |
| Q3 2015 | $24,660,000 | +31.4% | 2,250,000 | +50.0% | 2.11% | +65.3% |
| Q2 2015 | $18,765,000 | – | 1,500,000 | – | 1.28% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Camber Capital Management LP | 3,500,000 | $60,060,000 | 2.02% |
| ACT CAPITAL MANAGEMENT, LLC | 161,500 | $2,772,000 | 1.42% |
| Rhenman & Partners Asset Management AB | 950,000 | $16,302,000 | 1.11% |
| MAVERICK CAPITAL LTD | 5,761,073 | $98,860,000 | 0.93% |
| Birchview Capital, LP | 72,000 | $1,236,000 | 0.74% |
| Bellevue Group AG | 4,101,404 | $70,380,000 | 0.69% |
| CM Management, LLC | 50,000 | $858,000 | 0.62% |
| Duquesne Family Office | 1,000,000 | $17,160,000 | 0.42% |
| OSTERWEIS CAPITAL MANAGEMENT INC | 373,368 | $6,407,000 | 0.33% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 67,000 | $1,149,000 | 0.30% |